Sun is still struggling with faults at Halol

Sun Pharmaceutical Industries is preparing its responses to three ‘Form 483’ observations of deficiencies resulting from a re-inspection of the firm’s key Halol, India, formulations facility by the US Food and Drug Administration (FDA) from 12-23 February.